- Home
- KNF vs PRAX Comparison
KNF vs PRAX Comparison
Compare KNF & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNF | PRAX |
|---|---|---|
| Founded | 1917 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KNF | PRAX |
|---|---|---|
| Price | $73.03 | $288.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $96.43 | ★ $373.79 |
| AVG Volume (30 Days) | 456.2K | ★ 790.5K |
| Earning Date | 02-12-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.61 | N/A |
| Revenue | ★ $3,048,164,000.00 | $7,463,000.00 |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $5.84 | $12,467.71 |
| P/E Ratio | $26.94 | ★ N/A |
| Revenue Growth | 5.52 | ★ 364.98 |
| 52 Week Low | $58.72 | $26.70 |
| 52 Week High | $108.83 | $317.72 |
Technical Indicators
Market Signals| Indicator | KNF | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 64.69 |
| Support Level | $70.28 | $285.95 |
| Resistance Level | $73.92 | $317.72 |
| Average True Range (ATR) | 1.82 | 12.78 |
| MACD | -0.58 | -0.99 |
| Stochastic Oscillator | 28.09 | 46.62 |
Price Performance
Historical ComparisonAbout KNF Knife Riv Holding Co.
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. Its segments include Pacific, Northwest, Mountain, North Central, South, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.